{"schema_version":"secwatch.filing_event.v1","accession":"0001665988-26-000026","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2026-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.696421+00:00","generated_at":"2026-05-14T22:46:55.895536+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance","bullets":["Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).","Adjusted EBITDA $23.9M (+24% from $19.2M); cash from ops $8.9M vs -$19.3M.","Pain Treatments +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%; International +17.1%.","Raised FY26 Adj EPS guidance to $0.75-$0.79 (up $0.02), CFO to $84-$89M (up $2M); reaffirms rev $600-610M.","Discretionary $22M term loan prepayment on Mar 27 reduces debt and future interest."],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-26-000026","json":"https://secwatch.observer/filing/0001665988-26-000026.json","markdown":"https://secwatch.observer/filing/0001665988-26-000026.md","text":"https://secwatch.observer/filing/0001665988-26-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/bvs-20260506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:46:55.895536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f38ebbc252b120765987fbaeba43a22e2abd456","claim":"Bioventus Inc. reported three months ended March 28, 2026 results: revenue $132.1 million, net income $3.1 million, EPS $0.04 per diluted share. Guidance raised.","evidence_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001493152-26-026777","ticker":"IVF","company_name":"INVO Fertility, Inc.","filed_at":"2026-06-02T12:40:33+00:00","headline":"INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026777","json":"https://secwatch.observer/filing/0001493152-26-026777.json","markdown":"https://secwatch.observer/filing/0001493152-26-026777.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"and technologies,\ntoday announced fiscal year 2025 financial results. FY2025\nFinancial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue\n was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated\n clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue\n from all clinics was $8,021,929, including","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315226026777/0001493152-26-026777-index.htm"}},{"accession":"0001493152-26-026770","ticker":"POLA","company_name":"Polar Power, Inc.","filed_at":"2026-06-02T12:30:26+00:00","headline":"Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026770","json":"https://secwatch.observer/filing/0001493152-26-026770.json","markdown":"https://secwatch.observer/filing/0001493152-26-026770.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/form8-k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1622345/000149315226026770/0001493152-26-026770-index.htm"}},{"accession":"0001104659-26-069202","ticker":"CTRN","company_name":"Citi Trends Inc","filed_at":"2026-06-02T10:58:00+00:00","headline":"Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069202","json":"https://secwatch.observer/filing/0001104659-26-069202.json","markdown":"https://secwatch.observer/filing/0001104659-26-069202.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/tm2616574d1_8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"(EXHIBIT 99.1) ---\n\nEX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER\nFISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth\nof 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million;\nQ1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1318484/000110465926069202/0001104659-26-069202-index.htm"}},{"accession":"0001628280-26-039379","ticker":null,"company_name":"DAVEY TREE EXPERT CO","filed_at":"2026-06-01T17:50:11+00:00","headline":"Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039379","json":"https://secwatch.observer/filing/0001628280-26-039379.json","markdown":"https://secwatch.observer/filing/0001628280-26-039379.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/davey-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"Exchange Act, unless such subsequent filing specifically references this Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nTo Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm"}},{"accession":"0000029332-26-000027","ticker":"DXYN","company_name":"DIXIE GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029332-26-000027","json":"https://secwatch.observer/filing/0000029332-26-000027.json","markdown":"https://secwatch.observer/filing/0000029332-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/dxyn-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}},{"accession":"0001104659-26-058204","ticker":"EXPI","company_name":"eXp World Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058204","json":"https://secwatch.observer/filing/0001104659-26-058204.json","markdown":"https://secwatch.observer/filing/0001104659-26-058204.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/agnt-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm"}},{"accession":"0001104659-26-058287","ticker":"BATRA","company_name":"Atlanta Braves Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Atlanta Braves Holdings Q1 revenue up 53% to $72M; operating loss narrows to $41M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058287","json":"https://secwatch.observer/filing/0001104659-26-058287.json","markdown":"https://secwatch.observer/filing/0001104659-26-058287.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/batra-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"For the first quarter, worldwide revenue of $132.1 million advanced 7%, driven by growth across all three areas of the Company's broad portfolio. Net income attributable to Bioventus Inc. was $3.1 million, compared to a net loss attributable to Bioventus Inc. of $2.6 million in the prior-year period. Adjusted EBITDA* of $23.9 million advanced 24% from $19.2 million in the prior-year period as a result of higher revenue growth, increased gross profit and favorable foreign currency movements. GAAP earnings of $0.04 per diluted share of Class A common stock improved from the diluted loss of $0.04 per share in the prior-year period.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000026/0001665988-26-000026-index.htm","comparable_excerpt":"Total revenue grew to $72 million in the first quarter of 2026, up 53% from the prior year period.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}